Imaging of Integrins as Biomarkers for Tumor Angiogenesis

被引:156
作者
Cai, Weibo [1 ,2 ,3 ,4 ]
Niu, Gang [1 ,2 ]
Chen, Xiaoyuan [1 ,2 ]
机构
[1] Stanford Univ, Sch Med, Dept Radiol, MIPS, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, BioX Program, Stanford, CA 94305 USA
[3] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA
[4] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53706 USA
关键词
Angiogenesis; integrins; molecular imaging; cancer; biomarker; integrin alpha(v)beta(3); positron emission tomography; molecular medicine;
D O I
10.2174/138161208786404308
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The integrin family plays important roles during tumor angiogenesis, the formation of new blood vessels from pre-existing vasculature. Traditional structural and functional imaging techniques are not sufficient for early lesion detection, patient stratification, or monitoring the therapeutic efficacy against cancer. Molecular imaging, the visualization, characterization and measurement of biological processes at the molecular and cellular levels in humans and other living systems, can fulfill these goals. In this review article, we will summarize the current state-of-the-art of imaging integrin (alpha(2)beta(1),alpha(3)beta(1), alpha(4)beta(1), alpha(v)beta(3), and alpha(v)beta(6)) expression using either single molecular imaging modality (magnetic resonance imaging, untrasound, optical, single photon emission computed tomography, and positron emissiom tomography) or a combination of different modalities. For clinical translation, radionuclide-based imaging will have broad potential applications in cancer patients and the currently available clinical data (exclusively on integrin alpha(v)beta(3) so far) will be discussed in detail. The design, optimization, and characterization of imaging agents targeting integrins will be presented and areas needing extensive future research effort will be discussed. In the new era of personalized medicine, fast clinical translation and incorporation of integrin imaging into anti-cancer clinical trials will be critical for the maximum benefit of cancer patients.
引用
收藏
页码:2943 / 2973
页数:31
相关论文
共 324 条
[41]   Are quantum dots ready for in vivo imaging in human subjects? [J].
Cai, Weibo ;
Hsu, Andrew R. ;
Li, Zi-Bo ;
Chen, Xiaoyuan .
NANOSCALE RESEARCH LETTERS, 2007, 2 (06) :265-281
[42]   Nanoplatforms for targeted molecular imaging in living subjects [J].
Cai, Weibo ;
Chen, Xiaoyuan .
SMALL, 2007, 3 (11) :1840-1854
[43]   Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression [J].
Cai, Weibo ;
Chen, Xiaoyuan .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :4267-4279
[44]   Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody [J].
Cai, Weibo ;
Chen, Kai ;
He, Lina ;
Cao, Qizhen ;
Koong, Albert ;
Chen, Xiaoyuan .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (06) :850-858
[45]   How molecular imaging is speeding up antiangiogenic drug development [J].
Cai, Weibo ;
Rao, Jianghong ;
Gambhir, Sanjiv S. ;
Chen, Xiaoyuan .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2624-2633
[46]   In vitro and in vivo characterization of 64Cu-labeled Abegrin™ a humanized monoclonal antibody against integrin αvβ3 [J].
Cai, Weibo ;
Wu, Yun ;
Chen, Kai ;
Cao, Qizhen ;
Tice, David A. ;
Chen, Xiaoyuan .
CANCER RESEARCH, 2006, 66 (19) :9673-9681
[47]  
Cai Weibo, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P407, DOI 10.2174/187152006778226530
[48]  
Cai WB, 2006, J NUCL MED, V47, P1172
[49]   Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates [J].
Caliceti, P ;
Veronese, FM .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (10) :1261-1277
[50]   PET imaging of acute and chronic inflammation in living mice [J].
Cao, Qizhen ;
Cai, Weibo ;
Li, Zi-Bo ;
Chen, Kai ;
He, Lina ;
Li, Hui-Cheng ;
Hui, Mizhou ;
Chen, Xiaoyuan .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (11) :1832-1842